Akero Therapeutics Inc (AKRO NASDAQ) stock market data APIs
$52.5862
1.97(3.7%)
as of July 18, 2025
Try our APIs with
free plan!
Akero Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
52.5862
Open
54.5544
High
54.5544
Low
51.5707
52 wk Range
21.34-58.4
Market Cap
4 331 M
Shares Outstanding
79 718 K
EPS
-0.9
Beta
-0.16
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akero Therapeutics Inc data using free add-ons & libraries
Get Akero Therapeutics Inc Fundamental Data
Akero Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -306 329 504
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.9917
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akero Therapeutics Inc News
New
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals RCKT announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adeno-associated virus (AAV)-based gene therapy, RP-...
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called...
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
Mirum Pharmaceuticals MIRM has delivered a stellar performance over the past three months. Shares of the company have rallied 35% compared with the industry’s rise of 6.9%. The stock has also outper...
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related macular...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
